- George Zimmerman will not be charged in domestic dispute
- Russian officials press bilateral U.S. trade deal
- Selfies at Funerals blog creator retires after Obama flub: ‘Our work here is done’
- New Obama adviser Podesta is against Keystone but will steer clear of pipeline deliberations
- 40 Australian adults, children found in ‘one of the worst accounts of incest ever made public’
- Venezuela’s Maduro calls on student ‘price vigilantes’ to hit the streets, report businesses
- Atheists smug as Hindus join Satanists to demand display at Oklahoma Statehouse
- Bow before Valkyrie, NASA’s ‘superhero robot’ entry in DARPA challenge
- 10-year-old Pennsylvania boy suspended for pretend bow-and-arrow shooting
- Budget deal exposes GOP divisions; conservatives slam tax hikes, vague cuts
Latest Pharmaceutical Research Items
India's handling of intellectual property rights and patents has raised the ire of lawmakers on Capitol Hill, governors from across the nation, business leaders and pharmaceutical giants — and if that path continues, analysts say, the economic relationship between the two nations may come to a grinding halt.
With three months to go before Election Day, President Obama's campaign manager faced a fusillade of questions Wednesday about whether he deliberately skirted disclosure rules during his time as deputy White House chief of staff, undermining the administration's claim to be "the most transparent administration in history."
House Republicans last week released their second investigative memo detailing how the White House worked with the nation's drug companies to sell President Obama's health care law, arguing the deals he struck violate his campaign pledges of transparency.
The top two U.S. companies managing prescription drug benefits are uniting in a $29.1 billion deal they say will help achieve key goals of the health care overhaul: reining in costs and improving patients' health.